Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MNC Products Retain Dominance In Korea As Local Generics Face Challenges

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Multinational company products covered by South Korea's national medical insurance system were the most prescribed last year, according to recent government data

You may also be interested in...



Korean Dong-A In Talks With Warner Chilcott For Additional Indications For ED Drug Zydena

SEOUL - South Korea's Dong-A Pharmaceutical says its U.S. partner Warner Chilcott is seeking an expanded indication of lower urinary track symptoms for its erectile dysfunction drug Zydena (udenafil)

GSK Expands In Korea With Purchase Of 9.9 Percent Equity Stake In Dong-A Pharma

SEOUL - GlaxoSmithKline is paying KRW142.9 billion ($128.7 million) to acquire a 9.9 percent stake in South Korea's leading Dong-A pharmaceutical and OTC company. The strategic alliance should help GSK gain market share in the rapidly growing Korean pharmaceutical market

Korea's Anti-Rebate Laws Seen Sparking More Demand For MNC Products

SEOUL - Last week's passage of long-awaited "anti-rebate laws" that enable courts to punish both contributors and receivers of rebates, could trigger more demand from doctors to prescribe branded products from multinational companies, industry watchers said

Related Content

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel